ArticleBMC neurology2026
A rare presentation of pediatric MOG-antibody-associated neuroretinitis: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroretinitis (NR) is an uncommon inflammatory optic neuropathy characterized by optic disc edema and macular exudates. Although NR may arise from infectious or idiopathic causes, its association with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is exceptionally rare in children. Early recognition is critical, as MOGAD-related ocular involvement can respond favorably to prompt immunotherapy. CASE PRESENTATION: We report an 11-year-old girl presenting with acute, painless visual loss in the right eye following one week of ocular pain with eye movements. Ophthalmologic evaluation revealed marked optic disc edema, splinter hemorrhages, and early macular exudation. MRI demonstrated right optic nerve thickening with T2-FLAIR hyperintensity, and optical coherence tomography showed subretinal fluid extending to the fovea. Extensive infectious testing was negative. Serum MOG-IgG was positive, supporting a diagnosis of MOGAD-associated NR. The patient received high-dose intravenous corticosteroids followed by intravenous immunoglobulin (IVIG), resulting in rapid visual improvement. A partial macular star developed during the early recovery phase. Maintenance therapy with mycophenolate mofetil was initiated due to IVIG intolerance and continued for 24 months. Over a 3-year follow-up period, the patient experienced full visual recovery without clinical relapses, although residual optic nerve thinning was observed on MRI.
conclusionThis case highlights a rare pediatric presentation of MOGAD manifesting as NR and underscores the importance of considering MOG-IgG testing in children presenting with optic disc edema and macular exudation. Early and sustained immunotherapy can lead to complete visual recovery and may reduce the risk of recurrent demyelinating episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.